Back to results

Ox1r agonists for the treatment of autoimmunity diseases

Patent Application number: European Procedure (Patents) (EPA) - 24 Juin 2014 - 14 305 990.5
Inventors:
MESSAL Nassima,OGIER-DENIS Eric,VOISIN Thierry,TRETON Xavier

Reference:

BIO14095-T1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 24-06-2014
Rare disease: No
Second indication: No

You might also be interested in

RT00623

Hrln (hrar alpha) cell line

HRLN were generated by transfection of cervical cancer HeLa cells with the […]

Read more
RT00626

Ug5ln gal4-hmr cell line

UG5LN were generated by transfection of osteocarcinoma cancer U2OS cells with the […]

Read more
RT00625

Ug5ln cell line

UG5LN were generated by transfection of osteocarcinoma cancer U20S cells with the […]

Read more
RT00624

Ualh cell line

UALH were generated by transfection of osteocarcinoma cancer U2OS cells with the […]

Read more
RT00586

Ualh har cell line

UALH were generated by transfection of osteocarcinoma cancer U2OS cells with the […]

Read more
RT00582

Palm cell line

PALM were generated by co-transfection of cervical cancer PC3 cells with the […]

Read more
RT00583

Meln (her alpha) cell line

MELN were generated by transfection of breasr cancer MCF-7 cells with the […]

Read more
RT00589

Hmln (hgr) cell line

HMLN were generated by transfection of cervical cancer HeLa cells with the MMTV- […]

Read more
RT00621

Hg5ln gal4-rtr beta cell line

HG5LN were generated by transfection of cervical cancer HeLa cells with the […]

Read more
RT00620

Heln hrar alpha cell line

HELN were generated by transfection of cervical cancer HeLa cells with the […]

Read more
RT00558

Hg5ln gal4-hppar alpha cell line

HG5LN were generated by transfection of cervical cancer HeLa cells with the […]

Read more
RT00559

Hg5ln gal4-hppar gamma cell line

HG5LN were generated by transfection of cervical cancer HeLa cells with the […]

Read more